Recurrent Clostridioides difficile infection: Recognition, management, prevention

被引:18
|
作者
Tsigrelis, Constantine [1 ,2 ]
机构
[1] Cleveland Clin, Dept Infect Dis, G21,9500 Euclid Ave, Cleveland, OH 44195 USA
[2] Case Western Reserve Univ, Lerner Coll Med, Cleveland Clin, Cleveland, OH 44106 USA
关键词
FECAL MICROBIOTA TRANSPLANTATION; CLINICAL-PRACTICE GUIDELINES; HEALTH-CARE EPIDEMIOLOGY; INTESTINAL MICROBIOME; DISEASES SOCIETY; VANCOMYCIN; BEZLOTOXUMAB; UPDATE; ADULTS; FIDAXOMICIN;
D O I
10.3949/ccjm.87gr.20001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Clostridioides difficile infection (CDI) is the most common cause of diarrhea in hospitalized patients and results in substantial morbidity, mortality, and costs. Its clinical management, primarily with antibiotics, is often complicated by recurrent episodes. These recurrent CDI episodes are thought to be caused by antibiotic disruption of colonic microbiota and usually occur within 4 weeks of completing antibiotic therapy. The risk of recurrent CDI increases after the first episode, creating a need for management strategies to diagnose, treat, and prevent these complications.
引用
收藏
页码:347 / 359
页数:13
相关论文
共 50 条
  • [1] Prevention and treatment of recurrent Clostridioides difficile infection
    Shin, Jae Hyun
    Warren, Cirle A.
    CURRENT OPINION IN INFECTIOUS DISEASES, 2019, 32 (05) : 482 - 489
  • [2] Ursodeoxycholic Acid for the Management of Recurrent Clostridioides difficile Infection
    Perreault, Gabriel
    Baylor, Jessica
    Radin, Arielle
    Javitt, Norman
    Chen, Lea Ann
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S824 - S825
  • [3] Recent developments in the management of recurrent Clostridioides difficile infection
    Mendo-Lopez, Rafael
    Villafuerte-Galvez, Javier
    White, Nicole
    Mahoney, Monica, V
    Kelly, Ciaran P.
    Alonso, Carolyn D.
    ANAEROBE, 2020, 62
  • [4] Live Biotherapeutic Products for the Prevention of Recurrent Clostridioides difficile Infection
    Pettit, Natasha N.
    Shaeer, Kristy M.
    Chahine, Elias B.
    ANNALS OF PHARMACOTHERAPY, 2024, 58 (12) : 1204 - 1217
  • [5] Emerging Options for the Prevention and Management of Clostridioides difficile Infection
    Gonzales-Luna, Anne J. J.
    Carlson, Travis J. J.
    Garey, Kevin W. W.
    DRUGS, 2023, 83 (02) : 105 - 116
  • [6] Emerging Options for the Prevention and Management of Clostridioides difficile Infection
    Anne J. Gonzales-Luna
    Travis J. Carlson
    Kevin W. Garey
    Drugs, 2023, 83 : 105 - 116
  • [7] Oral Vancomycin as Secondary Prophylaxis for Prevention of Recurrent Clostridioides difficile Infection
    Chang, Leslie L.
    Allegretti, Jessica
    Skinner, Andrew M.
    Dubberke, Erik R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (07): : 654 - 656
  • [8] Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection With a Focus on Immunocompromised Patients
    Askar, Sally F.
    Kenney, Rachel M.
    Tariq, Zain
    Conner, Ruth
    Williams, Jonathan
    Ramesh, Mayur
    Alangaden, George J.
    JOURNAL OF PHARMACY PRACTICE, 2023, 36 (03) : 584 - 587
  • [9] Management of Clostridioides difficile Infection
    Clarkin, Christina
    Quist, Stephanie
    Shamis, Renata
    King, Amber E.
    Shah, Bhavik M.
    CRITICAL CARE NURSE, 2019, 39 (05) : E1 - E12
  • [10] Vowst's FDA approval is a boon for the prevention of recurrent Clostridioides difficile infection
    Anand, Ayush
    Shaikh, Nameera Parveen
    Aggarwal, Yash
    Fatima, Umaima
    Chapagain, Sanskriti
    Chidurala, Rahul
    Vaghela, Jenish
    Surana, Arihant
    Parikh, Charmy
    Patel, Raj H.
    ANNALS OF MEDICINE AND SURGERY, 2023, 85 (12): : 5852 - 5854